The beginning of the end for EU specialities?

Baker, John
October 2005
European Chemical News;10/31/2005, Vol. 83 Issue 2169, p5
Trade Publication
This article reports on the effort of Asian producers to acquire assets in Europe as of October 2005. It was said that such efforts were made to gain market access and technology. According to reports, Avecia revealed it has struck a deal to sell its pharmaceutical custom synthesis business in Great Britain and North America to India's Nicholas Piramal. Western companies' efforts to sustain competitiveness through innovation and customer service are increasingly seeming to be ineffective against the onslaught of Asian produce and investment.


Related Articles

  • Avecia agrees custom synthesis business sale. Robinson, Simon // European Chemical News;10/31/2005, Vol. 83 Issue 2169, p6 

    This article reports on the decision of British specialty chemicals maker Avecia to sell its pharmaceutical custom synthesis business to Indian pharmaceutical company Nicholas Piramal as of October 2005. The deal includes all Avecia Pharmaceuticals assets and operations in Huddersfield, England,...

  • DIGEST.  // Chemical Week;3/31/2004, Vol. 166 Issue 11, p43 

    Presents news briefs on the pharmaceutical and fine chemicals industries as of March 31, 2004. Contract awarded to Bachem to manufacture the peptide drug candidate Lcatibant for Jerini, a private startup pharma company; Collaboration of pharma and fine chemicals firm Nicholas Piramal with Vera...

  • Nicholas Piramal to spin off. Desai, Suresh Thakur // Chemical Business;May/Jun98, Vol. 12 Issue 5/6, p95 

    Reports on the approval by shareholders of Nicholas Piramal of the spin-off of the glass and bulk drug units.

  • Nicholas Piramal net rises by 23%. Desai, Suresh Thakur // Chemical Business;May/Jun98, Vol. 12 Issue 5/6, p95 

    Reports on the financial performance of Nicholas Piramal India Ltd. in the fiscal period 1997-98.

  • NPIL sets ambitious growth targets. Jarvis, Lisa // Chemical Market Reporter;4/18/2005, Vol. 267 Issue 16, p32 

    Highlights the growth targets of Mumbai, India-based Nicholas Piramal India Ltd. Company's plan to leverage the "India advantage" of low-cost, high quality manufacturing as well as its own long track record of multinational partnerships and strong stance respecting intellectual property laws;...

  • Swati Piramal. BOSE, DEEPTI KHANNA // Business Today;10/7/2007, Vol. 16 Issue 20, p84 

    The article profiles Swati Piramal, director of Nicholas Piramal Ltd., one of the biggest pharmaceutical companies in India. She is the only woman member on the Scientific Advisory Board of the Prime Minister. It is noted that she played a significant role in the drug maker's transformation. As...

  • Technology Watch: Catalyst Immobilization With Avecia's EnCat. Boswell, Clay // Chemical Market Reporter;12/8/2003, Vol. 264 Issue 20, pFR13 

    Focuses on the significance of Avecia's debut of a catalyst immobilization technology called Encat. Impact on the usefulness of homogenous catalysis in pharmaceutical synthesis; Advantages over crystallization or chromatography in removing chemical impurities.

  • Avecia sells biocides to Arch. Beacham, Will // European Chemical News;3/8/2004, Vol. 80 Issue 2090, p6 

    Reports on the sale of the biocides business of British speciality chemicals firm Avecia to U.S. group Arch Chemicals. Value of the sale; Number of common stock shares to be received by Avecia under the deal; Number of staff that will transfer employment to Arch.

  • Lubrizol to Buy Avecia's Color Additives Unit. Walsh, Kerri // Chemical Week;1/7/2004, Vol. 166 Issue 1, p9 

    Reports on the decision of Lubrizol to acquire the color additives business of Avecia in January 2004. Details of the deal; Plans of Lubrizol for the acquired unit; Views of bond analysts regarding the move of Avecia.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics